References from scientific journals

Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.

Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K. Yokoya Y, et al. J Gastroenterol. 2019 Dec;54(12):1083-1095. doi: 10.1007/s00535-019-01609-2. Epub 2019 Aug 8. J Gastroenterol. 2019. PMID: 31396703

BACKGROUND: Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabepraz …
BACKGROUND: Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), …

Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.

Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.

Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole …
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.

Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Sakurai Y, et al. Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21. Aliment Pharmacol Ther. 2015. PMID: 26193978 Free article. Clinical Trial.

METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabeprazole 10 mg (Study V vs. R) were orally administered daily for 7 days. ...RESULTS: Acid-inhibitory effect (pH4 HTR) of vonoprazan w …
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or r …

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.

Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. Ochoa D, et al. BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.

We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. METHOD: Subjects were evaluated to determine the …
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study popu …

Rabeprazole.

Prakash A, Faulds D. Prakash A, et al. Drugs. 1998 Feb;55(2):261-7; discussion 268. doi: 10.2165/00003495-199855020-00009. Drugs. 1998. PMID: 9506245 Review.

Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. Rabeprazole has 2- to 10-fold greater antisecretory activity than o …
Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition …

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Li XQ, Andersson TB, Ahlström M, Weidolf L. Li XQ, et al. Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821. Drug Metab Dispos. 2004. PMID: 15258107

To compare the potency and specificity of the currently used PPIs (i.e., omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) as inhibitors of four cytochrome P450 enzymes (CYP2C9, 2C19, 2D6, and 3A4), we performed in vitro studies using human live …
To compare the potency and specificity of the currently used PPIs (i.e., omeprazole, esomeprazole, lansoprazole, pantoprazole, and …

Rabeprazole.

Desai CA, Samant BD. Desai CA, et al. J Postgrad Med. 2002 Jan-Mar;48(1):80-1. J Postgrad Med. 2002. PMID: 12082341 Free article. No abstract available.


Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.

Yago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Yago MR, et al. Mol Pharm. 2013 Nov 4;10(11):4032-7. doi: 10.1021/mp4003738. Epub 2013 Sep 10. Mol Pharm. 2013. PMID: 23980906 Free PMC article. Clinical Trial.

Six healthy volunteers with baseline normochlorhydria (fasting gastric pH rabeprazole twice daily for four days. On the fifth day, an additional 20 mg dose of oral rabeprazole

…

Six healthy volunteers with baseline normochlorhydria (fasting gastric pH …


The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.

Park CH, Kim EH, Roh YH, Kim HY, Lee SK. Park CH, et al. PLoS One. 2014 Nov 13;9(11):e112558. doi: 10.1371/journal.pone.0112558. eCollection 2014. PLoS One. 2014. PMID: 25394217 Free PMC article. Review.

METHODS: We conducted a systematic search of MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "proton pump," "dexlansoprazole," "esomeprazole," "ilaprazole," "lansoprazole," "omeprazole," "pantoprazole," "rabeprazole," "hypomagnesemia," "hypomagnesaemia …
METHODS: We conducted a systematic search of MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "proton pump," "dexlansopr …

Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.

Chan FK, Kyaw M, Tanigawa T, Higuchi K, Fujimoto K, Cheong PK, Lee V, Kinoshita Y, Naito Y, Watanabe T, Ching JY, Lam K, Lo A, Chan H, Lui R, Tang RS, Sakata Y, Tse YK, Takeuchi T, Handa O, Nebiki H, Wu JC, Abe T, Mishiro T, Ng SC, Arakawa T. Chan FK, et al. Gastroenterology. 2017 Jan;152(1):105-110.e1. doi: 10.1053/j.gastro.2016.09.006. Epub 2016 Sep 15. Gastroenterology. 2017. PMID: 27641510 Clinical Trial.

RESULTS: During the 12-month study period, upper GI bleeding recurred in 1 patient receiving rabeprazole (0.7%; 95% confidence interval [CI], 0.1%-5.1%) and in 4 patients receiving famotidine (3.1%; 95% CI, 1.2%-8.1%) (P = .16). The composite end point of recurrent bleedin …
RESULTS: During the 12-month study period, upper GI bleeding recurred in 1 patient receiving rabeprazole (0.7%; 95% confidence interv …